Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation

AIMS/HYPOTHESIS: Sodium–glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) constitute a novel class of glucose-lowering (type 2) kidney-targeted agents. We recently reported that the SGLT2i empagliflozin (EMPA) reduced cardiac cytosolic Na(+) ([Na(+)](c)) and cytosolic Ca(2+) ([Ca(2+)](c)) concentr...

Descripción completa

Detalles Bibliográficos
Autores principales: Uthman, Laween, Baartscheer, Antonius, Bleijlevens, Boris, Schumacher, Cees A., Fiolet, Jan W. T., Koeman, Anneke, Jancev, Milena, Hollmann, Markus W., Weber, Nina C., Coronel, Ruben, Zuurbier, Coert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448958/
https://www.ncbi.nlm.nih.gov/pubmed/29197997
http://dx.doi.org/10.1007/s00125-017-4509-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448958/
https://www.ncbi.nlm.nih.gov/pubmed/29197997
http://dx.doi.org/10.1007/s00125-017-4509-7

Ejemplares similares